Loading...
XTAI
3164
Market cap58mUSD
Jun 13, Last price  
20.00TWD
1D
0.50%
1Q
-10.91%
Jan 2017
-14.89%
IPO
28.04%
Name

GenMont Biotech Inc

Chart & Performance

D1W1MN
No data to show
P/E
30.22
P/S
4.49
EPS
0.66
Div Yield, %
2.50%
Shrs. gr., 5y
-1.68%
Rev. gr., 5y
2.16%
Revenues
385m
+21.18%
352,848,000514,577,000286,214,000226,821,000308,937,000564,525,000534,719,000540,780,000552,941,000406,532,000346,244,000325,191,000427,929,000368,546,000318,015,000385,373,000
Net income
57m
+73.54%
86,234,000147,542,00038,159,00028,890,00030,891,000-386,158,000-98,028,000-235,938,00045,600,000158,019,00057,451,00060,884,000113,132,00056,978,00032,991,00057,251,000
CFO
124m
+258.24%
108,533,000200,034,00039,937,000-25,239,000100,371,000-61,996,000-5,010,00045,337,00077,559,00056,032,00074,515,000118,273,000111,658,000137,948,00034,599,000123,946,000
Dividend
Jun 17, 20240.5 TWD/sh

Profile

GenMont Biotech Incorporation engages in the research, development, production, and sale of functional probiotic products in Taiwan. The company also offers probiotics with special functions; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.
URL
https://www.genmont.com.tw/
IPO date
Jun 12, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
385,373
21.18%
318,015
-13.71%
368,546
-13.88%
Cost of revenue
345,255
310,290
308,364
Unusual Expense (Income)
NOPBT
40,118
7,725
60,182
NOPBT Margin
10.41%
2.43%
16.33%
Operating Taxes
16,968
5,732
18,797
Tax Rate
42.30%
74.20%
31.23%
NOPAT
23,150
1,993
41,385
Net income
57,251
73.54%
32,991
-42.10%
56,978
-49.64%
Dividends
(43,256)
(60,460)
(95,008)
Dividend yield
2.61%
2.83%
4.63%
Proceeds from repurchase of equity
2,814
BB yield
-0.13%
Debt
Debt current
35,124
4,598
1,060
Long-term debt
120,153
89,669
68,030
Deferred revenue
Other long-term liabilities
2,318
2,368
2,368
Net debt
(28,496)
(306,260)
(91,117)
Cash flow
Cash from operating activities
123,946
34,599
137,948
CAPEX
(44,054)
(33,308)
(70,933)
Cash from investing activities
(82,423)
(75,374)
(83,704)
Cash from financing activities
12,554
(36,817)
(91,085)
FCF
37,698
40,759
9,647
Balance
Cash
425,813
328,302
400,943
Long term investments
(242,040)
72,225
(240,736)
Excess cash
164,504
384,626
141,780
Stockholders' equity
1,121,029
1,072,020
1,136,347
Invested Capital
1,436,103
1,125,171
1,363,915
ROIC
1.81%
0.16%
3.06%
ROCE
2.50%
0.51%
3.99%
EV
Common stock shares outstanding
82,000
86,570
86,660
Price
20.20
-18.22%
24.70
4.22%
23.70
-2.67%
Market cap
1,656,400
-22.54%
2,138,279
4.11%
2,053,842
-2.76%
EV
1,755,802
1,964,834
2,108,618
EBITDA
111,710
72,505
110,597
EV/EBITDA
15.72
27.10
19.07
Interest
3,718
973
755
Interest/NOPBT
9.27%
12.60%
1.25%